OphRx

Company Overview

Snapshot

Founded in January 2014, OphRx operates with 1–10 employees. The company has raised $1 million across one funding round from four investors. OphRx is currently in the preclinical stage of development for two product candidates, OPH-101 and OPH-100, targeting wet AMD and dry eye syndrome respectively.

Business overview

OphRx is a Health Tech and Life Sciences company specializing in noninvasive drug delivery for ocular treatments. The company develops eye drops utilizing lyotropic liquid crystals as an alternative to traditional delivery methods, such as intra-vitreal injections, for treating diseases affecting both the front and back of the eye. Its core technology platform is being applied to product candidates like OPH-101 for wet AMD and OPH-100 for dry eye syndrome, serving the pharmaceuticals and ophthalmology markets.

Company Intelligence Q&A

What is OphRx's primary focus in drug delivery?

OphRx focuses on developing noninvasive drug-delivery technology for ocular use, utilizing lyotropic liquid crystals in eye drops as an alternative to methods like intra-vitreal injections for treating eye diseases.

What are OphRx's main product candidates currently in development?

OphRx is developing OPH-101 as a topical treatment for wet AMD and OPH-100 as a treatment for dry eye syndrome. Both are currently in the preclinical stage of development.

Which company fully owns XLVision Sciences, the parent company of OphRx?

OphRx is a XLVision Sciences company, which is fully owned by BioLight Life Sciences Investments.

What is the total capital raised by OphRx?

OphRx has raised a total of $1 million across one funding round.

What is the employee count for OphRx?

OphRx currently has 1–10 employees.